Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Comparison among three different antithrombotic strategies after percutaneous LAA occlusion with a Watchman FLX LAAC device.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Texas Cardiac Arrhythmia Research Foundation
• Treatments: Clopidogrel

Criteria

Inclusion Criteria:

• Men and women ≥18 years of age

• Successful LAAC procedure (device implanted without procedural or bleeding complication).

• Patients contraindicated or unsuitable for long-term OAC.

• History of AF (permanent or persistent or paroxysmal).

• Written informed consent by the patient or designee if the patient is unable to consent

Exclusion Criteria:

• Life expectancy < 2 years.

• Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.

• Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data